AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24343476
Drug: Risperidone (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (0.6 mg/day)
Trial: 22499474
Drug: Weekly EBP-structured
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly EBP-structured case conference (Group A)
Trial: 10643545
Drug: Morphine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (5 mg for seven opioid-naïve patients and 3.75 mg for two patients on top of their regular oral dose of 7.5 mg q4 h)
Trial: 21332799
Drug: 1.6 g
RxNorm normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 g eicosapentaenoic acid (EPA) and 1.1 g docosahexaenoic acid (DHA) supplementation
Trial: 19125875
Drug: Dexamethasone +
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone + intravenous metoclopramide + diphenhydramine
Trial: 19125875
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + intravenous metoclopramide + diphenhydramine
Trial: 17223212
Drug: Glucose-insulin-potassium (GIK)
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-insulin-potassium (GIK) infusion at 2 ml/kg body weight per hour for 12 hours
Trial: 15321001
Drug: Inhaled insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled insulin via AERx iDMS
Trial: 31596802
Drug: Multimodal surgical-site
RxNorm normalized name: SOLO SITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal surgical-site injection (ropivacaine 200 mg, epinephrine 0.6 mg, and morphine 5 mg)
Trial: 28329334
Drug: DRV 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV 800 mg QD
Trial: 28329334
Drug: DRV 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV 600 mg BID
Trial: 18043700
Drug: Multivitamin (MV)
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multivitamin (MV) tablet
Trial: 9535242
Drug: 25 microg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 microg/ml vancomycin added to PN
Trial: 29768414
Drug: Low-dose autologous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose autologous AdMSC (1x10^6 cells/kg)
Trial: 29768414
Drug: High-dose autologous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose autologous AdMSC (4x10^6 cells/kg)
Trial: 24278924
Drug: Implants placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants placed at the bone level (Group 0)
Trial: 24278924
Drug: Implants placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants placed 1 mm below the alveolar crest (Group 1)
Trial: 24278924
Drug: Implants placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants placed 2 mm below the alveolar crest (Group 2)
Trial: 24278924
Drug: Implants in
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants in groups 1 and 2 compared to Group 0
Trial: 21929307
Drug: Chemotherapy (fludarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (fludarabine and cyclophosphamide without rituximab)
Trial: 19099859
Drug: Carvedilol plus
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol plus traditional regimen (digoxin, prednisone and/or diuretics)
Trial: 19099859
Drug: Traditional regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional regimen (digoxin, prednisone and/or diuretics)
Trial: 11841719
Drug: Morphine-Adcon-L (M-ADL)
RxNorm normalized name: morphine sulfate Extended Release Oral Capsule [M-Eslon]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-Adcon-L (M-ADL)
Trial: 8087777
Drug: Data collection
RxNorm normalized name: NO DATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Data collection on current medications
Trial: 578772
Drug: Etozolin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etozolin (400 mg)
Trial: 578772
Drug: Etozolin (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etozolin (1200 mg)
Trial: 578772
Drug: Vs (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vs (75 mg)
Trial: 27896440
Drug: Treosulfan intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treosulfan intravenous (i.v.) 7000 mg/m2 d1 q4w
Trial: 27896440
Drug: Treosulfan oral
RxNorm normalized name: treosulfan Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treosulfan oral (p.o.) 600 mg/m2 d1-28 q8w
Trial: 27896440
Drug: Treosulfan intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treosulfan intravenous (i.v.)
Trial: 27896440
Drug: Treosulfan oral
RxNorm normalized name: treosulfan Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treosulfan oral (p.o.)
Trial: 23417891
Drug: Taurolidine solution
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurolidine solution
Trial: 23417891
Drug: Heparin solution
RxNorm normalized name: heparin Injectable Solution
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin solution
Trial: 23417891
Drug: Standard group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard group (Heparin)
Trial: 9155592
Drug: Oral theophylline
RxNorm normalized name: theophylline Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral theophylline (240 mg)
Trial: 8292702
Drug: Enoximone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone 0.5 mg/kg (after halothane and isoflurane)
Trial: 29894374
Drug: Mindfulness-based stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based stress reduction intervention; 20 weekly, 1.5-hour sessions
Trial: 27770787
Drug: Optimized virgin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized virgin olive oil with high phenolic content (OVOO, 429 mg/Kg)
Trial: 27770787
Drug: Functional olive
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional olive oil (FOO, 429 mg/Kg phenolic compounds, 389 mg/Kg triterpenic acids)
Trial: 24430787
Drug: Lifestyle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifestyle intervention and treatment with voglibose or nateglinide
Trial: 12582226
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group - standard behavioral weight loss program with 14 weekly sessions
Trial: 10852458
Drug: Cabergoline (CAB)
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline (CAB) treatment at doses ranging from 0.25-3.5 mg weekly for 1-3 years
Trial: 10852458
Drug: Cabergoline (CAB)
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline (CAB) treatment at doses ranging from 0.25-1 mg weekly for 1-6 months
Trial: 10852458
Drug: Cabergoline (CAB)
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline (CAB) treatment at doses ranging from 1-2 mg weekly for 6-12 months and 3-3.5 mg weekly for 18-24 months
Trial: 10852458
Drug: Cabergoline (CAB)
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline (CAB) treatment at doses ranging from 1-2 mg weekly for 1-6 months and 3 mg weekly for 12 months
Trial: 9356099
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) infused intravenously at a rate of 0.3 g/kg
Trial: 9356099
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (NTG) infused intravenously at a rate of 5 g/kg
Trial: 8449049
Drug: Albuterol by
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol by nebulizer plus placebo by inhaler (n = 20)
Trial: 8449049
Drug: Albuterol by
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol by inhaler plus placebo by nebulizer (n = 15)
Trial: 29873864
Drug: Nonsurgical periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonsurgical periodontal therapy (personalized oral hygiene instructions, subgingival scaling, and root planing per quadrant)
Trial: 29873864
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (received equal treatment after the study period)
Trial: 11823390
Drug: Intravenous nalbuphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nalbuphine and propacetamol (NP)
Trial: 10065346
Drug: Sustained-release lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release lithium carbonate (HP matrix)
Trial: 10065346
Drug: Sustained-release lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release lithium carbonate (L matrix)
Trial: 7668664
Drug: Clarion cochlear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarion cochlear implant
Trial: 7668664
Drug: Nucleus implant
RxNorm normalized name: Sus scrofa thalamus lateral geniculate nucleus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleus implant
Trial: 6777233
Drug: Intravenous hyperalimentation
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hyperalimentation (IVH) with total bowel rest
Trial: 6777233
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (prednisone 40 mg/day)
Trial: 21868730
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg recombinant tissue-type plasminogen activator (rtPA)
Trial: 19154802
Drug: Oral erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral erythromycin (EM) 600 mg/day, n=18
Trial: 17356094
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg bid of nebulized recombinant human deoxyribonuclease (rhDNase)
Trial: 11106230
Drug: XR9576 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XR9576 2.0 mg/kg i.v.
Trial: 11106230
Drug: XR9576 >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XR9576 > or = 200 mg/volunteer p.o.
Trial: 11106230
Drug: XR9576 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XR9576 (various doses)
Trial: 8443849
Drug: Nasal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal ketamine 6 mg.kg‐1
Trial: 8443849
Drug: Promethazine and
RxNorm normalized name: Promethazine and Phenylephrine Hydrochloride Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine and meperidine 1 mg.kg‐1 each (Control)
Trial: 30629148
Drug: All PAMVAC
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All PAMVAC formulations
Trial: 28110412
Drug: KDIGO bundle
RxNorm normalized name: oxymetazoline
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KDIGO bundle (optimization of volume status and hemodynamics, avoidance of nephrotoxic drugs, preventing hyperglycemia)
Trial: 15079128
Drug: Chemotherapy (31
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (31 patients)
Trial: 15079128
Drug: Postoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative treatment (overall)
Trial: 15079128
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy (overall)
Trial: 11463561
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (cisplatin 100 mg/m² on day 1 and etoposide 120 mg/m² on days 1-3 for six cycles)
Trial: 12526358
Drug: Traditional combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional combined therapy with a predominance of balanced solution
Trial: 8070497
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of the ACE inhibitor perindoprilat
Trial: 29420063
Drug: Random spice
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Random spice isolates producing enterotoxin at levels of 4 to 16 ng/mL
Trial: 26139307
Drug: Golimumab (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golimumab (50 mg subcutaneously every 4 weeks)
Trial: 11453957
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment, average daily dose 2.4 IU (SD 0.86)
Trial: 9209724
Drug: Continuing treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing treatment
Trial: 9209724
Drug: Successful tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Successful tapering off medication
Trial: 3042317
Drug: Clofibrate (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofibrate (1.5 g/day)
Trial: 31679120
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg Oxycodone Tamper-Resistant Tablet (OTR)
Trial: 31679120
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg OXYCONTIN® (OXY)
Trial: 30942008
Drug: Follow-up after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up after treatment (Observation group)
Trial: 28268074
Drug: Inactivated zoster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated zoster vaccine (ZVIN), 4-dose regimen (∼30 days between doses)
Trial: 17012141
Drug: Oral beta‐1,3/1,6‐glucan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral beta‐1,3/1,6‐glucan 700 mg (Group 1)
Trial: 17012141
Drug: Oral beta‐1,3/1,6‐glucan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral beta‐1,3/1,6‐glucan 1400 mg (Group 2)
Trial: 12709037
Drug: Aggressive multiple-infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aggressive multiple-infusion episode-based protocol
Trial: 12709037
Drug: Individualized escalating
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized escalating dose and frequency of routine replacement infusions of factor concentrate
Trial: 7015795
Drug: Captopril (75-450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (75-450 mg daily)
Trial: 7015795
Drug: Captopril (75-450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (75-450 mg daily) + Hydrochlorothiazide (50-100 mg daily)
Trial: 7015795
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Hydrochlorothiazide (50-100 mg daily)
Trial: 28486709
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy (NRT; lozenge, patch, both)
Trial: 28486709
Drug: Bupropion (alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (alone or with nicotine lozenge)
Trial: 20717875
Drug: HMC05 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMC05 (500 mg tablets, 3 times daily for 4 weeks)
Trial: 20717875
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 mg tablets, 3 times daily for 4 weeks)
Trial: 15705087
Drug: No prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylactic alpha-blocker
Trial: 12385927
Drug: Prophylactic alpha-blockers
RxNorm normalized name: ALPHA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic alpha-blockers
Trial: 15705087
Drug: Supplemental radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental radiotherapy and/or androgen deprivation therapy
Trial: 12851876
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil 10‐mg therapy for 48 weeks
Trial: 8740244
Drug: Pravastatin 10
RxNorm normalized name: pravastatin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 10 mg for 1 month, 20 mg for 1 month, 40 mg for 4 months
Trial: 6761123
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release oxprenolol 160 mg twice daily
Trial: 30863632
Drug: High-dose IQP-AE-103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IQP-AE-103
Trial: 30863632
Drug: Low-dose IQP-AE-103
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IQP-AE-103
Trial: 28209040
Drug: Essential diagnosis
RxNorm normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential diagnosis and treatment services
Trial: 26022508
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (DEX) - bolus dose of 0.5 µg·kg‐1 within 10 min, maintenance dose of 0.5 µg·kg‐1·h‐1
Trial: 26022508
Drug: Etomidate (ETO)
RxNorm normalized name: Etomidate
DrugBank: Etomidate (DB00292)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etomidate (ETO) - bolus dose of 0.3 mg·kg‐1 without maintenance dose
Trial: 22284296
Drug: Continuous forces
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous forces (150 g) applied with 0.017 × 0.025-in Beta III Titanium cantilever springs, reactivated every 2 weeks
Trial: 22284296
Drug: Continuous forces
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous forces (150 g) applied with 0.017 × 0.025-in Beta III Titanium cantilever springs, reactivated every 3 weeks
Trial: 22284296
Drug: Continuous forces
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous forces (150 g)
Trial: 19573637
Drug: Whole-cell pertussis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-cell pertussis (DTwP//Hib+oral poliomyelitis vaccine [OPV]) combination vaccine
Trial: 17877658
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors (SSRIs) including fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram
Trial: 72237
Drug: Oral disopyramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral disopyramide (100 mg four times daily)
Trial: 31374589
Drug: Coronary artery
RxNorm normalized name: Drug-coated coronary artery stent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coronary artery bypass grafting (CABG) with optimal medical therapy (OMT)
Trial: 23388527
Drug: EPO therapy
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPO therapy (3 times per week for 6 months)
Trial: 27737664
Drug: naproxen 1000
RxNorm normalized name: naproxen 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen 1000 mg
Trial: 19567491
Drug: In-hospital treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-hospital treatment of OSA using auto-adjusting positive airway pressure along with standard treatment of ADHF
Trial: 19567491
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for ADHF
Trial: 17012419
Drug: Pamidronate (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (90 mg single dose)
Trial: 15268624
Drug: Twice-weekly humanised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly humanised anti-IL-6R monoclonal antibody (MRA)
Trial: 1604411
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral administration of CN-100 at a dose of 150 mg
Trial: 1604411
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral administration of CN-100 at a dose of 300 mg
Trial: 1604411
Drug: Repetitive oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive oral administration of CN-100 at a daily dose of 300 mg
Trial: 1604411
Drug: Repetitive oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive oral administration of CN-100
Trial: 3728891
Drug: Physostigmine 2
RxNorm normalized name: PHYSostigmine 2 mg/5 mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine 2 mg i.v. prior to extubation
Trial: 29240641
Drug: Low-dose insulin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose insulin injections
Trial: 26129928
Drug: Antioxidant group
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant group (500 mg of vitamin C and 117.5 mg vitamin E before and after training)
Trial: 12393113
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 4.3 microg.kg(‐1) plus IV 0.9% saline (Group 1)